Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for mitigation of severe adverse reactions from oral VEGFR-targeted therapy in advanced gastric cancer, non-small cell lung cancer, and osteosarcoma
ChiCTR1800016856Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jul 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thalidomide, Rivoceranib and anlotinib in gastric cancer (GC), non-small cell lung cancer (NSCLC) and osteosarcoma (OS) (8 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: Incidence of diarrhea, Incidence of bleeding and 4 more. Started Jul 2018; status: recruiting.
02
Drugs
thalidomideRivoceranibanlotinib
03
Conditions
gastric cancer (GC)non-small cell lung cancer (NSCLC)osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR1800016856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016856.